MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma). According to GlobalData, Phase II drugs for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MIL-62’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MIL-62 overview

MIL-62 is under development for the treatment of chronic lymphocytic leukemia, relapsed/refractory and previously untreated follicular lymphoma,  relapsed/refractory and newly diagnosed diffuse large B cell lymphoma, mantle cell lymphoma and intranodal marginal zone lymphoma, systemic lupus erythematosus (SLE), extranodal marginal zone lymphoma, splenic marginal zone lymphoma, lupus nephritis, primary membranous nephropathy, myasthenia gravis, neuromyelitis optica, relapsed/refractory B-cell non-Hodgkin lymphoma. The drug candidate is administered by intravenous drip route and acts by targeting cells expressing B-lymphocyte antigen CD20. It is a biobetter.

Beijing Mabworks Biotech overview

Beijing Mabworks Biotech (Beijing Mabworks Biotech Co) that develops and designs new prototype humanized and fully human monoclonal antibodies, oncology drugs, and other products. The company is headquartered in Beijing, Beijing, China.

For a complete picture of MIL-62’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.